Safety Reading Notes

Read safety context beside the research guide.

The CBC and target/pharmacology source set should still be read with safety context in mind. Mechanistic or preclinical evidence should not be converted into consumer instructions, and product identity can change how closely a source applies. PMID 21749363

PubMed For Dummies Article

CBC and target/pharmacology Evidence Review: the long-form source walk-through

Quick read
  • CBC and target/pharmacology currently has 26 source-backed evidence row(s), so this page should be read as a research guide rather than a single conclusion. PMID 21749363
  • The evidence classes most visible in the row language are insufficient (16), and mechanistic or pharmacological (10). PMID 37764262
  • The study-design language most visible in the row language is Narrative or expert review (9), Cellular or in vitro study (7), Animal study (5), and other mapped categories (1). PMID 38777605
  • The repeated topics are receptor, transporter, target, metabolic, or pharmacology mechanisms (26), which tells the reader where to start opening PubMed and DOI links. PMID 40872492

Start with the research question

CBC and target/pharmacology is built from 26 source-backed evidence row(s) and 26 research source(s). The current evidence classes read as insufficient (16), and mechanistic or pharmacological (10), and the study-design language most often reads as Narrative or expert review (9), Cellular or in vitro study (7), Animal study (5), and other mapped categories (1). PMID 21749363

The row-level question is not simply whether CBC and target/pharmacology is "good" or "bad." The useful question is what each row studied, what evidence class it received, and whether the source is close to the reader's actual question. The most repeated row topics are receptor, transporter, target, metabolic, or pharmacology mechanisms (26). PMID 35306000

Human evidence 0 rows

Rows involving human participants, patients, or clinical source language. These rows are closer to everyday reader questions, but still depend on population, dose, route, comparator, and endpoint. PMID 40006604

Preclinical evidence 0 rows

Animal, cellular, or model-based rows. These can explain why a topic is being studied, but they should not be read as human-health instructions. PMID 35306000

Mechanistic evidence 10 rows

Rows about receptors, enzymes, channels, metabolism, binding, signaling, or pharmacology. These explain plausibility without proving a consumer outcome. PMID 40967679

Limits and uncertainty 16 rows

Rows where safety, tolerability, risk, product limits, or insufficient evidence need to stay visible next to the rest of the article. PMID 28120231

The lane labels are not a quality score. They are a reading method: keep human evidence, preclinical evidence, mechanisms, and uncertainty in separate mental boxes before deciding what a source can actually support. PMID 27435265

Where this page has the most source density

The largest bucket surfaced for this page is receptor, transporter, target, metabolic, or pharmacology mechanisms: insufficient. That does not automatically mean the topic is settled; it means this is where the current source trail is densest. The next visible bucket is receptor, transporter, target, metabolic, or pharmacology mechanisms: mechanistic or pharmacological, which gives readers another way to see what the literature repeatedly circles. PMID 21749363

Source density should be read with evidence posture. A bucket can contain many rows and still be limited if the studies are indirect, mixed, preclinical, product-specific, or mostly review-level. The paragraphs below name the buckets directly and keep each explanation connected to a source record. PMID 35306000

Bucket chapters: what the literature is circling

receptor, transporter, target, metabolic, or pharmacology mechanisms: insufficient

16 research sources 16 rows (657-681) Evidence class: insufficient

This bucket summarizes source-backed rows focused on receptor, transporter, target, metabolic, or pharmacology mechanisms: insufficient. It currently draws from 16 research source(s), so the exact study type matters. PMID 21749363

Read this bucket as an uncertainty marker. The source trail exists, but the current evidence posture is not strong enough for a broad plain-English conclusion. PMID 21749363

  • Evidence row 657

    CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome... PMID 21749363

  • Evidence row 681

    CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome meas... PMID 38950639

receptor, transporter, target, metabolic, or pharmacology mechanisms: mechanistic or pharmacological

10 research sources 10 rows (662-682) Evidence class: mechanistic or pharmacological

This bucket summarizes source-backed rows focused on receptor, transporter, target, metabolic, or pharmacology mechanisms: mechanistic or pharmacological. It currently draws from 10 research source(s), so the exact study type matters. PMID 35306000

Read this bucket as mechanism or pharmacology context. Mechanisms can make the biology easier to understand, but they are not the same thing as a demonstrated effect in people. PMID 35306000

  • Evidence row 662

    CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro s... PMID 35306000

  • Evidence row 682

    CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms). PMID 35399958

Human evidence, mechanisms, and safety are different lanes

This page currently separates human evidence (0 row(s)), mechanistic evidence (10 row(s)), and safety/tolerability context (0 row(s)). That separation is the heart of the site. Mechanistic evidence can make a topic biologically interesting, but it should not silently become a human outcome. PMID 21749363

Human evidence still depends on population, dose, route, duration, product identity, and endpoint. Safety rows belong in the same reading path as benefit-oriented rows because formulation, co-exposures, prescription medications, impairment context, and higher-risk populations can change how close a source is to a reader's question. PMID 35306000

What this does and does not mean

  • It means the page has a traceable source trail. It does not mean every bucket has the same clinical strength. PMID 34838836
  • It means mechanisms, animal models, human studies, safety rows, and insufficient-evidence rows are being kept visible as separate evidence types. PMID 40046175
  • It does not turn a preclinical mechanism into a consumer recommendation, and it does not treat one product, dose, route, or population as interchangeable with another. PMID 40706771

How to use the source table

The source-backed evidence table below is the audit trail. Each row keeps a public sentence connected to a source record when a PubMed ID or DOI is available. If a sentence feels important, the reader should be able to click through, inspect the study type, and decide whether the source is close to the question they care about. PMID 21749363

This is why the public page is intentionally layered. The top gives the reader a fast orientation. The bucket table groups repeated rows into readable topics. The article body explains the buckets using the actual evidence-row language. The source notes below walk through every evidence row before the source table repeats the technical trace. PMID 35306000

Source-reading checklist for CBC and target/pharmacology

  1. Open the linked PubMed or DOI record. PMID 36654096
  2. Check whether the source studied humans, animals, cells, chemistry, pharmacology, product testing, or a review of prior literature. PMID 39769302
  3. Compare the source product, dose, route, population, and endpoint to the question being asked. PMID 31368508
  4. Look for safety, tolerability, drug-interaction, impairment, pregnancy, pediatric, psychiatric, cardiovascular, and product-quality context before treating the bucket as settled. PMID 40611782
  5. Return to the evidence table when the article summary sounds too broad; the row is the audit unit. PMID 33395525

Source Notes

CBC and target/pharmacology source-by-source reading notes

These notes pull every evidence row on this page into the readable article body before the source table repeats the audit trail. Each note keeps the row language beside the PubMed or DOI link when available.

  1. Evidence row 657

    CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms). PMID 21749363

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects.
  2. Evidence row 658

    CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms). PMID 37764262

    Evidence class: insufficient; Study design: Cellular or in vitro study. Source: Anti-Inflammatory Effects of Minor Cannabinoids CBC, THCV, and CBN in Human Macrophages.
  3. Evidence row 659

    CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms). PMID 38777605

    Evidence class: insufficient; Study design: Narrative or expert review. Source: The Potential of Cannabichromene (CBC) as a Therapeutic Agent.
  4. Evidence row 660

    CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms). PMID 40872492

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Phytocannabinoids as Novel SGLT2 Modulators for Renal Glucose Reabsorption in Type 2 Diabetes Management.
  5. Evidence row 661

    CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms). PMID 40006604

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Pharmacokinetics of Non-Psychotropic Phytocannabinoids.
  6. Evidence row 662

    CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms). PMID 35306000

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: In vitro evaluation of the interaction of the cannabis constituents cannabichromene and cannabichromenic acid with ABCG2 and ABCB1 transporters.
  7. Evidence row 663

    CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (study design: Meta-analysis or systematic evidence synthesis; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms). PMID 40967679

    Evidence class: insufficient; Study design: Meta-analysis or systematic evidence synthesis. Source: Chemical diversity, receptor binding affinity, and pharmacology of phytocannabinoids: Insights into neuronal mechanisms.
  8. Evidence row 664

    CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms). PMID 28120231

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Molecular Pharmacology of Phytocannabinoids.
  9. Evidence row 665

    CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms). PMID 27435265

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoids, inflammation, and fibrosis.
  10. Evidence row 666

    CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms). PMID 34838836

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabis: Chemistry, extraction and therapeutic applications.
  11. Evidence row 667

    CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms). PMID 40046175

    Evidence class: insufficient; Study design: Narrative or expert review. Source: The Pharmacology of Cannabinoids in Chronic Pain.
  12. Evidence row 668

    CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms). PMID 40706771

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Effects of cannabidiol, cannabichromene, cannabidivarin, cannabigerol and cannabinol in endometrial cells: Implications for endocrine and senescence modulation.
  13. Evidence row 669

    CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms). PMID 36654096

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabigerol and cannabichromene in Cannabis sativa L.
  14. Evidence row 670

    CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms). PMID 39769302

    Evidence class: insufficient; Study design: Animal study. Source: Cannabichromene as a Novel Inhibitor of Th2 Cytokine and JAK/STAT Pathway Activation in Atopic Dermatitis Models.
  15. Evidence row 671

    CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms). PMID 31368508

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Cannabichromene is a cannabinoid CB2 receptor agonist.
  16. Evidence row 672

    CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms). PMID 40611782

    Evidence class: insufficient; Study design: Animal study. Source: Effect of Quantitative Structural Properties and Drug Formulation in Four Cannabinoids (Cannabidiol, Cannabigerol, Cannabichromene, and Cannabinol) on Their Lymphatic Transport after Enteral Administration in Rats.
  17. Evidence row 673

    CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Animal study; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms). PMID 33395525

    Evidence class: insufficient; Study design: Animal study. Source: Cannabichromene, Related Phytocannabinoids, and 5-Fluoro-cannabichromene Have Anticonvulsant Properties in a Mouse Model of Dravet Syndrome.
  18. Evidence row 674

    CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms). PMID 40790027

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Cannabichromene: integrative modulation of apoptosis, ferroptosis, and endocannabinoid signaling in pancreatic cancer therapy.
  19. Evidence row 675

    CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms). PMID 39137108

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Activation of CB2 Receptors by (-)-Cannabichromene but Not (+)-Cannabichromene.
  20. Evidence row 676

    CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms). PMID 32315173

    Evidence class: mechanistic or pharmacological. Source: The Oxidation of Phytocannabinoids to Cannabinoquinoids.
  21. Evidence row 677

    CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms). PMID 37023389

    Evidence class: insufficient. Source: Natural Cannabichromene (CBC) Shows Distinct Scalemicity Grades and Enantiomeric Dominance in Cannabis sativa Strains.
  22. Evidence row 678

    CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms). PMID 40271542

    Evidence class: mechanistic or pharmacological. Source: Structure and Dynamics of Cannabinoid Binding to the GABAA Receptor.
  23. Evidence row 679

    CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms). PMID 23373571

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: The cannabinoid TRPA1 agonist cannabichromene inhibits nitric oxide production in macrophages and ameliorates murine colitis.
  24. Evidence row 680

    CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms). PMID 22300105

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Inhibitory effect of cannabichromene, a major non-psychotropic cannabinoid extracted from Cannabis sativa, on inflammation-induced hypermotility in mice.
  25. Evidence row 681

    CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms). PMID 38950639

    Evidence class: insufficient; Study design: Cellular or in vitro study. Source: Selected phytocannabinoids inhibit SN-38- and cytokine-evoked increases in epithelial permeability and improve intestinal barrier function in vitro.
  26. Evidence row 682

    CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms). PMID 35399958

    Evidence class: mechanistic or pharmacological. Source: In silico discovery of non-psychoactive scaffolds in Cannabis halting SARS-CoV-2 host entry and replication machinery.